Shanghai Securities News China Securities Network News (reporter Confucius Ziyuan) Frontier Biology issued an announcement of stock trading changes. The company's research product FB2001 is an injectable new crown pneumonia virus protease inhibitor, the target is the new crown pneumonia virus 3CL main protease, as of the disclosure date of this announcement, the world's same target new drug has been Pfizer's oral new crown drug (Paxlovid) has been authorized for emergency use by the US Food and Drug Administration (FDA) for the treatment of mild to moderate new crown pneumonia patients with poor prognosis risk, non-hospitalization, the company's product FB2001 is an injectable protease inhibitor, It is intended to be used to treat hospitalized patients with moderate and severe COVID-19; currently approved drugs for the treatment of hospitalized patients with COVID-19 include Remdesivir of Gilead Corporation. Investors are kindly requested to make rational decisions and invest prudently.
【Company Report】
Shanghai Securities News China Securities Network News (reporter Confucius Ziyuan) Frontier Biological Announcement, the company received the State Food and Drug Administration approved and issued the "Drug Clinical Trial Approval Notice", anti-new crown virus drug injection FB2001 drug clinical Phase I bridging trial application was approved. FB2001 is a protease inhibitor of new crown pneumonia virus (SARS-CoV-2), which is a peptide-like compound designed and synthesized based on the three-dimensional structure (3CL) of the coronavirus master protease, which has the activity of efficiently targeting and inhibiting the coronavirus master protease and the anti-new coronavirus in vitro, and at the same time shows good in vivo pharmacokinetic properties and safety in experimental animals. The Company has reached a partnership with the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences to obtain the right to clinically develop, manufacture, manufacture and commercialize the new drug candidate FB2001 (DC series of drug candidates) on a global scale.
Shanghai Securities News China Securities Network News (reporter Confucius Ziyuan) Frontier Biological Announcement, the company received the "Notice of Grant of Invention Patent Right" issued by the State Intellectual Property Office, and after substantive review, made a notice of granting patent rights to the company's "stable Abbot Weitai composition". The present invention relates to a composition comprising HIV-1 fusion inhibitor Ekonin (generic name: Ebolvirte / Ebolwertide), including liquid compositions and stable lyophilized compositions, further providing a process of preparation thereof, and these compositions for preventing, treating or preventing the use of diseases caused by HIV. After the invention patent of "Stable Abbotsvetite Composition" is patented in China, the patent protection period will be until May 7, 2039. The approval of the patent of the invention is conducive to the company's continuous maintenance of the leading edge of the core product Aikenin technology, and is conducive to enhancing the company's comprehensive competitiveness.
![Musk: My family and I have been vaccinated against mandatory vaccinations[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)